|
|
|
市場調查報告書
全球生長因子（血液和組織）市場
Growth Factors ( Blood And Tissue )
|
全球生長因子（血液和組織）市場 是由出版商Global Industry Analysts, Inc.在2011年01月所出版的。
這份英文市場調查報告書包含Pages: 521 價格從美金4500起跳。
本報告書為血液與組織生長因子市場概要、產業課題、市場前景，同時包含研究開發、主要企業、各國市場的動向等，概述如下。
第1章 導論、方法論、產品定義
第2章 導論
- 生長因子：概要
- 現在以及將來分析
- 各地區分析
- 生長因子類別分析
- 生長因子作用與相關應用 其他
第3章 市場動向
- 受到專利失效影響的大企業
- 專利失效刺激了競争與銷售量
- 副作用：仍被擔心
- 法規體制評論
- 細胞因子
- 腦部神經營養因子
- 隨著年紀增加而發生的疾病
- Copaxone的新應用
- 生長因子模仿藥
第4章 業界課題
- 具有費用效果之方法開發
- 腦細胞的發達對神經營養因子之影響
- 干擾素和利巴韋林用造成的貧血
第5章 生長因子：概要
- 血液生長因子
- 組織生長因子
- 生長因子的組織修復之作用機構
- 血管形成因子
- 生長因子用途
第6章 主要研究開發
第7章 劃時代的開發
第8章 產品上市
第9章 近年的業界活動
第10章 過去業界活動：前景
第11章 全球主要相關企業
第12章 世界市場前景
第13章 美國
第14章 日本
第15章 歐洲
第16章 其他諸國
競爭檔案
Abstract
This report analyzes the worldwide markets for Growth Factors (Blood And
Tissue) in US$ Million by the following growth factor types: Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors, Interferons, &
Interleukins), and Tissue Growth Factors. The report provides separate
comprehensive analytics for the US, Japan, Europe, and Rest of World.Annual
estimates and forecasts are provided for the period 2007 through 2015. Also, a
seven-year historic analysis is provided for these markets.The report profiles
88 companies including many key and niche players such as Alseres
Pharmaceuticals, Inc., Amgen, Inc., Bayer HealthCare Pharmaceuticals Inc.,
BioMimetic Therapeutics, Inc., Biopharm GmbH, Bolder Biotechnology, Inc.,
Ceregene Inc., FibroGen Inc., FzioMed Inc., Novo Nordisk A/S, Reliance
GeneMedix Plc, Insmed Inc., Johnson & Johnson, Janssen-Ortho, Inc., Lonza
Group, Maxygen, Inc., Merck Serono International S.A., NsGene A/S, PeproTech,
Inc., Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai
Pharmaceutical Co. Ltd., Genentech, Inc., Shantha Biotechnics, Scil Proteins
GmbH, and Wockhardt Ltd. Market data and analytics are derived from primary
and secondary research. Company profiles are mostly extracted from URL
research and reported select online sources.
Table of Contents
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
- Study Reliability and Reporting Limitations 1
- Disclaimers 2
- Data Interpretation & Reporting Level 2
- Quantitative Techniques & Analytics 3
- Product Definitions and Scope of Study 3
- Blood Growth Factors 4
- Erythropoietins 4
- Colony Stimulating Factors 4
- Interferons 4
- Interleukins 4
- Tissue Growth Factors 4
2. INTRODUCTION 6
- Growth Factors: A Preface 6
- Current and Future Analysis 6
- Analysis By Region 6
- US - The Single Largest Market 6
- Growth Factors Market in Europe 6
- Market for Growth Factors in Rest of World 6
- Table 1: World Market for Growth Factors (2007-2015): Geographic
Regions Ranked by CAGR - US, Japan,Rest of World, and Europe (includes
corresponding Graph/Chart) 7
- Analysis by Growth Factor Type 7
- Growth Factors: Their Role and Related Applications 8
- Growth Factors: Adding a New Dimension 8
- Growth Factors: Classification Based on Activity 8
- Recent Trends & Developments 8
- Recombinant Human Erythropoietin: Gradually Gaining Dominance 9
- Leading EPO Drugs Worldwide 9
- Market Comparison of Erythropoietin-Based Drugs in America and European
Union 9
- Patent Expiries of Major Biopharmaceutical Drugs: 2001-2007 10
- Patent Expiries of Select Biopharmaceuticals in Europe and United
States: 2010 and Beyond 10
3. MARKET DYNAMICS 11
- Major Companies Impacted by Patent Expiries 11
- Patent Expiries Fuel Competition and Sales 11
- Side Effects - Still a Concern 11
- CDER- A Regulatory Review Authority for Growth Factors 11
- Innovative Delivery System Shows Potential for Accelerating Use of Growth
Factors 12
- Cytokines- Vital Growth Propellers for the Future of New Drugs 12
- Brain Derived Neurotrophic Factor (BDNF) Finds Increased Application 12
- Age-Related Diseases - Their Influence on Effective Therapies 12
- Mimetic Growth Factors - Exhibiting Promising Potential 13
- India - At the Center Stage... 13
4. INDUSTRY ISSUES 14
- Development of Cost Effective Methods - Need of the Hour 14
- Influence of Neurotrophic Factors on Brain Cell Development 14
- Combination of Interferons and Ribavirin Develops More Anemia Cases 14
5. GROWTH FACTORS - AN OVERVIEW 15
- Blood Growth Factors 15
- Erythropoietins 15
- Types of Erythropoietins 16
- Epoetin 16
- Darbepoetin 16
- Aranesp(r) 16
- Aranesp Vs. Other EPOs 16
- Recombinant Human EPO (rHuEPO) 16
- Table 2: World Market for Erythropoietins (2007-2015): Geographic
Regions Ranked by CAGR -Rest of World, Japan, US and Europe (includes
corresponding Graph/Chart) 17
- Colony Stimulating Factors 17
- Granulocyte-Colony Stimulating Factor 17
- Granulocyte Macrophage-Colony Stimulating Factor 18
- Other Colony Stimulating Factors 18
- Macrophage Colony Stimulating Factor (M-CSF) 18
- Key Functions of M-CSF 18
- Side-Effects of Colony-Stimulating Factors 18
- Table 3: World Market for Colony StimulatingFactors (2007-2015):
Geographic Regions Rankedby CAGR - Europe, US, Japan and Rest of
World(includes corresponding Graph/Chart) 19
- Interferons 19
- Types of Interferons 19
- Interferon-gamma 20
- 1a and 1b: Two Key Biochemical Forms of Interferon-β 20
- PEG-Intron 20
- Types of Interferons 20
- Table 4: World Market for Interferons as BloodGrowth Factors
(2007-2015): Geographic Regions Ranked by CAGR - US, Europe, Japan, andRest
of World (includes correspondingGraph/Chart) 21
- Interleukins 21
- Types of Interleukins 21
- Table 5: World Market for Interleukins as BloodGrowth Factors
(2007-2015): Geographic RegionsRanked by CAGR - Europe, Rest of World,
Japanand US (includes corresponding Graph/Chart) 22
- Tissue Growth Factors 23
- Wound Healing Growth Factors 23
- Neurotrophic Growth Factors 23
- Nerve Growth Factor 23
- Vascular Endothelial Growth Factor (VEGF) 23
- Fibroblast Growth Factor (FGF) 24
- Insulin-Like Growth Factor-I (IGF-I) 24
- Insulin-Like Growth Factor-II (IGF-II) 24
- Tissue Growth Factors: Classification Based on Key Source and Principal
Activity 24
- Platelet - Derived Growth Factors in Wound Healing 24
- Thrombopoietin (TPO) 25
- Table 6: World Market for Tissue Growth Factors(2007-2015): Geographic
Regions Ranked by CAGR -US, Europe, Japan, and Rest of World (includes
corresponding Graph/Chart) 25
- Growth Factors: Their Mode of Action in Tissue Repair 25
- Angiogenesis: Their Role in Wound Healing 26
- Angiogenesis As an Alternative for Cardiac Stents 26
- Applications of Growth Factors 26
- Growth Factors: Suppliers and Applications 27
- Growth Factors: Site/Course of Action and Applications 27
6. RESEARCH AND DEVELOPMENT HIGHLIGHTS A RECENT PAST PERSPECTIVE 28
- Maxygen Updates on Factor VII Program 28
- Evaluation of Extended Dosing Schedule of PROCRIT(r) 28
- PROCRIT(r) - A Better Option 28
- Nerve Growth Factor Shows Promising Potential Against Diabetes 28
- Cytokines and GM-CSF Found to be Closely Interlinked 29
- GM-CSF Enhances Rate of Survival in Neonates 29
- rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients 30
- rG-CSF- Their Influence on Preterm Infants with Sepsis 30
- Serum Macrophage Colony Stimulating Growth Factors Associated with
Thrombocyte and Monocyte 30
- Src Pathway Inactivation in Kit Impairs Blood Cell Growth and
Proliferation 30
- Cole Eye Institute Offers TIMP-3 Mechanism for Preventing Abnormal Growth
of Blood Vessels 31
- Effect of Brain Derived Neurotrophic Factor on Retinal Cells 31
- Orcel(tm) Exhibits High Growth Factor for Wound Healing and Cardiovascular
Applications 32
- Drug Combination of Macrophage Colony Stimulating Factor Shows Successful
Tolerance Levels 32
- Neotrofin(tm) Triggers Neurotrophic Factors 32
- G-CSF Shows Capability for Promoting Neutrophil Production 33
- Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates Wound Healing
Process 33
- Hepatocyte Growth Factors - Exhibiting Dual Role 34
- Cortex Pharmaceuticals Ampakines(r) Promotes Expression of Neurotrophin 34
- Granulocyte Colony Stimulating Factor Finds Application in Treating
Neonates 34
- Cerebrolysin Promotes Cognition 34
7. BREAKTHROUGHS - A RECENT PAST REVIEW 35
- Novel Set of Human Cytokines Unveiled 35
- IGFBP-3 and its Potential to Ward Off Gastric Cancer 35
- Bone Morphogenic Proteins Show Potential for Musculoskeletal Regeneration
35
- Growth Factors - Their Role in Preventing Heart Stroke 35
- Growth Factor Proteins Show Promising Results for Treating Cancer 35
- Neurotrophic Growth Factor - Primarily Responsible for Loss of Vision 36
- Redox-Active Grape Seed Exhibits Favorable Properties for Dermal Wound
Healing 36
- Role of Brain-Derived Neurotrophic Factor on Memory 36
- Nerve Growth Factor Found to Enhance Barium Current and Insulin Secretion
36
- Lipid Peroxidation May be Associated with Wound Healing 37
- Genentech Inc Unveils Molecule for Stimulating Growth of Blood Vessels 37
- Connective Tissue Growth Factor Found to Promote Lung Fibroblast 37
- Influence of Insulin-Like Growth Factor on Growth 38
- Regeneron Discovers Angiopoietins Targeted at Blood Vessel Growth and
Repair 38
- Environment and Insulin-Like Growth Factors Stimulate Risk of Cancer 38
- Cocktail of Neurotrophic Factors Promotes Regeneration of Torn Nerves 38
- Growth Factors Administration to Stimulate Tissue Repair 39
- Cytokine - Their Role in Combating Hepatitis C Virus 39
- Axokine(r) Yields Favorable Results Against Obesity 39
- Cell Genesys Unveils GDNF Gene Therapy Targeted Against Parkinson' s
Disease 39
8. PRODUCT LAUNCHES 40
- Sandoz Unveils Zarzio 40
- Wockhardt Launches Three Biotechnology Products 40
- Extavia(r) Receives Approval from European Commission 40
- Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric Patients 41
- Hospira Receives EC Approval on Retacrit 41
- Tercica Receives FDA Approval For Increlex 41
- Ventria Bioscience Introduces Lacromin 41
- Dragon Pharmaceuticals Bags Market Approval from Chinese SDA 41
- DPI Receives Approvals for Erythropoietin in Three New Markets 42
- Wockhardt Introduces Wepox Recombinant Erythropoietin Drug 42
- Shanta Biotechnics Unveils Shanferon 42
- SkinMedica Unveils TNS Recovery Complex(tm) Gel 42
- CellGenix Unveils Cytokines for Cell Applications 42
- Cel-Sci Corporation Develops Multikine 43 Wockhardt Limited Unveils
EPOX(tm) 43
9. RECENT INDUSTRY ACTIVITY 44
- Soluble Systems Collaborates with LifeNet Health' s Subsidiary to Introduce
TheraSkin(tm) 44
- GlaxoSmithKline and JCR Pharmaceuticals Enters into Partnership 44
- Kaken Pharmaceutical Enters into Licensing Agreement with Olympus
Corporation 44
- Biovitrum and Amgen Sign Agreement 45
- Merck Establishes Production Unit 45
- Eli Lilly and Company Acquires ImClone Systems 45
- GeneMedix Changes Name to Reliance GeneMedix 46
- FDA Approves Label Expansion for VIDAZA 46
- Pfizer Inks Exclusive Global Licensing Agreement with Scil Technology 46
- ZGEN Initiates Ph II Trial of Interleukin 21 47
- FzioMed Bags Health Canada Approval on Oxiplex(r) 47
- NsGene A/S Implants Encapsulated Cell in Patients 47
10. INDUSTRY ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER 48
- Reliance Life Sciences Takes Over Genemedix 48
- Fraunhofer Institute Introduces First Interferon Beta 1a to Treat Multiple
Sclerosis 48
- Shanghai Wanxing Inks Export Deal for Recombinant Human Interferon 48
- Hemispherx Enters into Distribution Agreement with Armada 49
- Bayer Establishes US Pharmaceuticals Subsidiary 49
- Merck Inks Agreement with Bristol-Myers Squibb and ImClone 49
- CoGenesys Signs Global Licensing Agreement with Vegenics 49
- InterMune Inks New Supply Deal with Boehringer Ingelheim 50
- Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals 50
- Cambrex Divests Bioproducts and Biopharma Subsidiaries 50
- Dragon Divests EPO Business 51
- Caregene and Genzyme Forms Partnership to Develop Cere-120 51
- NsGene to Undertake Phase Ib Clinical Trial of NsG0202 51
- Roche Receives European approval for NeoRecormon 51
- Bolder Receives Two U.S. Patents for Hematopoietic Factors 52
- RLS to Initiate Clinical Trials of Erythropoietin 52
- InterMune Drops Phase III trial of Interferon 52
- Chugai to Conduct Additional Trial on Epogin(r) 52
- Merck KGaA Acquires Serono Labs 52
- CytoPharm Acquires Low-Dose Interferon License from Amarillo Biosciences 53
- Hospira Signs Agreements with STADA and BIOCEUTICALS for Erythropoietin 53
- Biocon Bags GEAC Approval to Conduct Clinical Trial of Granulocyte Colony
Stimulating Factor 53
- SII to Conduct Clinical Trials of Rdna Products 53
- Claris to Construct Production Facility for EOP 54
- Mayne and Pliva to End Collaboration on Erythropoietin Development 54
- GeneMedix Collaborates with CJ Corp. 54
- FzioMed and USC Enter into Licensing Agreement for Oligopeptides 54
- AnGes MG Enters Into An Agreement with Vical 55
- Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA 55
- Dragon Pharmaceuticals Acquires Oriental Wave 55
- Insmed Enters into Exclusive Agreement with UCSF for IGF-1 Series 55
- Amrad and Ludwig Institute Jointly Focus on the Development of VEGF-B 55
- GeneMedix Restructures Business 56
- pSivida Limited Collaborates with Ian Wark Research Institute 56
- Amgen Acquires Tularik 56
- BMPI Signs up Luitpold Pharmaceuticals for FDA Approved GEM 21S(tm) 56
- Chugai and Roche Expand Drug Research Synergies 56
- Dragon Pharmaceuticals to Construct New Production Facility 57
- FibroGen Signs Contract with Yamanouchi for Licensing EPO Small Molecule 57
- Insmed and Tzamal Pharma Sign Agreement for Promoting SomatoKine 57
- Maxygen and Rentschler Enter into a Contract for G-CSF 57
- Maxygen Signs Agreement with Biovitrum for Manufacturing Beta Interferon 57
- Dragon Pharmaceuticals Signs Agreement with Zhongkai 58
- Dragon Pharmaceuticals Enters into Definitive Agreement with Oriental Wave
58
- Zymogenetics Bags US FDA Clearance 58
- Ceregene Bags Patent 58
- AME Enters into Third Collaboration with Eli Lilly and Company 58
- ViaCell Enters into Licensing Agreement and Collaboration with Amgen 59
- Ceregene Enters into Licensing Agreement with Genentech 59
- BIOPHARM GmbH Enters into Licensing Contract with DePuy 59
- Maxygen Enters into a Deal with Roche Holding 59
- GeneMedix Signs Agreement with SkyePharma 60
- Neurotech Enters into Licensing Agreement with Amgen 60
- Ceregene Enters into a Licensing Agreement with Washington University 60
- NeoTherapeutics Receives US Patent for Stimulating Neuritogenesis 60
- BioSET Bags Global Exclusive License for Novel Growth Factor Technology 60
- ViaCell Acquires Cerebrotec 60
- Fibrogen Collaborates with Sankyo 61
- Prescient NeuroPharma Collaborates with SRIB 61
- Dragon Pharmaceuticals Signs Agreement with Renapharm AB and Transworld 61
- Baxter Bags Exclusive Worldwide Rights for Epoetin Omega 61
- Ortec International Bags FDA PMA for OrCel 61
- GeneMedix Bags Chinese SDA Approval 62
- NsGene Collaborates with ARIAD Pharmaceuticals 62
- Regeneron Enters into Agreement with Emisphere Technologies 62
- NsGene A/S Signs Agreement with Biogen Inc 62
- NTB Enters into BioInformatics Outsourcing Agreement with HSC 63
11. FOCUS ON SELECT GLOBAL PLAYERS 64
- Alseres Pharmaceuticals, Inc. (USA) 64
- Amgen, Inc. (USA) 64
- Bayer HealthCare Pharmaceuticals Inc. (USA) 64
- BioMimetic Therapeutics, Inc. (USA) 65
- Biopharm GmbH (Germany) 65
- Bolder Biotechnology, Inc. (USA) 65
- Ceregene, Inc. (USA) 65
- FibroGen, Inc. (USA) 66
- FzioMed, Inc. (USA) 66
- Novo Nordisk A/S (Denmark) 66
- Reliance GeneMedix Plc. (UK) 66
- Insmed, Inc. (USA) 67
- Johnson & Johnson (USA) 67
- Janssen-Ortho, Inc. (Canada) 68
- Lonza Group (Switzerland) 68
- Maxygen, Inc. (USA) 68
- Merck Serono International S.A. (Switzerland) 69
- NsGene A/S (Denmark) 69
- PeproTech, Inc. (USA) 69
- Rentschler Biotechnologie GmbH (Germany) 69
- F. Hoffmann-La Roche Ltd (Switzerland) 70
- Chugai Pharmaceutical Co. Ltd. (Japan) 70
- Genentech, Inc. (USA) 70
- Shantha Biotechnics (India) 71
- Scil Proteins GmbH (Germany) 71
- Wockhardt Ltd. (India) 71
12. GLOBAL MARKET PERSPECTIVE 72
- Table 7: World Recent Past, Current & Future Analysis for Growth
Factors (Blood and Tissue) by Geographic Region -US, Japan, Europe, and Rest
of World Markets Independently Analyzed with Annual Sales in US$ Million for
Years2007 through 2015 (includes correspondingGraph/Chart) 72
- Table 8: World Historic Review for Growth Factors (Bloodand Tissue) by
Geographic Region - US, Japan, Europe,and Rest of World Markets Independently
Analyzed withAnnual Sales in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 73
- Table 9: World 11-Year Perspective for Growth Factors(Blood and Tissue) by
Geographic Region - Percentage Breakdown of Value Sales for US, Japan,
Europe,and Rest of World Markets for 2005, 2010 & 2015(includes
corresponding Graph/Chart) 74
- Table 10: World Recent Past, Current & Future Analysisfor Blood Growth
Factors by Geographic Region - US,Japan, Europe, and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for Years2007 through
2015 (includes correspondingGraph/Chart) 75
- Table 11: World Historic Review for Blood GrowthFactors by Geographic
Region - US, Japan, Europe,and Rest of World Markets Independently
Analyzedwith Annual Sales in US$ Million for Years 2000through 2006 (includes
correspondingGraph/Chart) 76
- Table 12: World 11-Year Perspective for Blood Growth Factors by Geographic
Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest
of World Markets for 2005,2010 & 2015 (includes corresponding Graph/Chart)
77
- Table 13: World Recent Past, Current & Future Analysisfor Blood Growth
Factors by Type - Erythropoietins,Colony Stimulating Factors, Interferons and
InterleukinsMarkets Independently Analyzed with Annual Salesin US$ Million for
Years 2007 through 2015(includes corresponding Graph/Chart) 78
- Table 14: World Historic Review for Blood Growth Factorsby Type -
Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins
Markets Independently Analyzedwith Annual Sales in US$ Million for Years 2000
through2006 (includes corresponding Graph/Chart) 79
- Table 15: World 11-Year Perspective for Blood GrowthFactors by Type -
Percentage Breakdown of Value Salesfor Erythropoietins, Colony Stimulating
Factors, Interferonsand Interleukins Markets for 2005, 2010 &
2015(includes corresponding Graph/Chart) 80
- Table 16: World Recent Past, Current & Future Analysis for
Erythropoietins by Geographic Region - US, Japan, Europe,and Rest of World
Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) 81
- Table 17: World Historic Review for Erythropoietins by Geographic Region -
US, Japan, Europe, and Rest of World Markets Independently Analyzed with
Annual Salesin US$ Million for Years 2000 through 2006(includes corresponding
Graph/Chart) 82
- Table 18: World 11-Year Perspective for Erythropoietins by Geographic
Region - Percentage Breakdown of Value Salesfor US, Japan, Europe, and Rest of
World Markets for 2005,2010 & 2015 (includes corresponding Graph/Chart) 83
- Table 19: World Recent Past, Current & Future Analysis for Colony
Stimulating Factors by Geographic Region - US,Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales in US$ Million for Years2007
through 2015 (includes correspondingGraph/Chart) 84
- Table 20: World Historic Review for Colony StimulatingFactors by
Geographic Region - US, Japan, Europe, andRest of World Markets Independently
Analyzed withAnnual Sales in US$ Million for Years 2000 through2006 (includes
corresponding Graph/Chart) 85
- Table 21: World 11-Year Perspective for Colony Stimulating Factors by
Geographic Region - Percentage Breakdown ofValue Sales for US, Japan, Europe,
and Rest of WorldMarkets for 2005, 2010 & 2015 (includes corresponding
Graph/Chart) 86
- Table 22: World Recent Past, Current & Future Analysis for Interferons
as Blood Growth Factors by Geographic Region -US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales in US$ Million for
Years2007 through 2015 (includes correspondingGraph/Chart) 87
- Table 23: World Historic Review for Interferons as BloodGrowth Factors by
Geographic Region - US, Japan, Europe,and Rest of World Markets Independently
Analyzed withAnnual Sales in US$ Million for Years 2000 through2006 (includes
corresponding Graph/Chart) 88
- Table 24: World 11-Year Perspective for Interferons asBlood Growth Factors
by Geographic Region - PercentageBreakdown of Value Sales for US, Japan,
Europe,and Rest of World Markets for 2005, 2010 & 2015(includes
corresponding Graph/Chart) 89
- Table 25: World Recent Past, Current & Future Analysisfor Interleukins
as Blood Growth Factors by GeographicRegion - US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales in US$ Millionfor Years
2007 through 2015 (includes corresponding Graph/Chart) 90
- Table 26: World Historic Review for Interleukins asBlood Growth Factors by
Geographic Region - US, Japan, Europe, and Rest of World Markets Independently
Analyzedwith Annual Sales in US$ Million for Years 2000 through2006 (includes
corresponding Graph/Chart) 91
- Table 27: World 11-Year Perspective for Interleukins asBlood Growth
Factors by Geographic Region - PercentageBreakdown of Value Sales for US,
Japan, Europe,and Rest of World Markets for 2005, 2010 & 2015(includes
corresponding Graph/Chart) 92
- Table 28: World Recent Past, Current & Future Analysisfor Tissue
Growth Factors by Geographic Region - US,Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales in US$ Million for Years2007
through 2015 (includes correspondingGraph/Chart) 93
- Table 29: World Historic Review for Tissue GrowthFactors by Geographic
Region - US, Japan, Europe, andRest of World Markets Independently Analyzed
withAnnual Sales in US$ Million for Years 2000 through2006 (includes
corresponding Graph/Chart) 94
- Table 30: World 11-Year Perspective for Tissue GrowthFactors by Geographic
Region - Percentage Breakdownof Value Sales for US, Japan, Europe, and Rest of
WorldMarkets for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 95
13. THE UNITED STATES 96
- A. Market Analysis 96
- Current and Future Analysis 96
- Leading EPO Drugs in the US 96
- B. Market Analytics 97
- Table 31: US Recent Past, Current & Future Analysisfor Growth
Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating
Factors, Interferonsand Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales in US$ Millionfor Years 2007
through 2015 (includes corresponding Graph/Chart) 97
- Table 32: US Historic Review for Growth Factors by Type - Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins) and Tissue Growth Factors Markets Independently Analyzed with
AnnualSales in US$ Million for Years 2000 through 2006(includes
corresponding Graph/Chart) 98
- Table 33: US 11-Year Perspective for Growth Factors by Type -
Percentage Breakdown of Value Sales for Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins)
and TissueGrowth Factors Markets for 2005, 2010 & 2015(includes
corresponding Graph/Chart) 99
14. JAPAN 100
- A. Market Analysis 100
- Current and Future Analysis 100
- Erythropoietin Market 100
- Leading EPO Drugs in Japan 100
- Market Scenario for Biotech Products 100
- Biotech Market Backed by Public Assistance 100
- B. Market Analytics 101
- Table 34: Japanese Recent Past, Current & FutureAnalysis for Growth
Factors by Type - Blood GrowthFactors (Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Salesin US$ Million for Years 2007
through 2015(includes corresponding Graph/Chart) 101
- Table 35: Japanese Historic Review for Growth Factorsby Type - Blood
Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins) andTissue Growth Factors Markets Independently Analyzedwith
Annual Sales in US$ Million for Years 2000through 2006 (includes
correspondingGraph/Chart) 102
- Table 36: Japanese 11-Year Perspective for GrowthFactors by Type -
Percentage Breakdown of Value Salesfor Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins)and Tissue Growth Factors Markets for 2005,2010 & 2015
(includes correspondingGraph/Chart) 103
15. EUROPE 104
- A. Market Analysis 104
- Current and Future Analysis 104
- Erythropoietin Market Scenario in the Recent Past 104
- Leading EPO Drugs in Europe 104
- B. Market Analytics 105
- Table 37: European Recent Past, Current & FutureAnalysis for Growth
Factors by Type - Blood GrowthFactors (Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins) and Tissue GrowthFactors Markets
Independently Analyzed with AnnualSales in US$ Million for Years 2007
through 2015(includes corresponding Graph/Chart) 105
- Table 38: European Historic Review for Growth Factorsby Type - Blood
Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins) andTissue Growth Factors Markets IndependentlyAnalyzed with
Annual Sales in US$ Million forYears 2000 through 2006
(includescorresponding Graph/Chart) 106
- Table 39: European 11-Year Perspective for GrowthFactors by Type -
Percentage Breakdown of Value Salesfor Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins)and Tissue Growth Factors Markets for 2005, 2010 &2015
(includes corresponding Graph/Chart) 107
16. REST OF WORLD 108
- A. Market Analysis 108
- Current and Future Analysis 108
- An Overview of Indian Market 108
- Erythropoietin 108
- G-CSF Market 109
- Interferon 109
- B. Market Analytics 110
- Table 40: Rest of World Recent Past, Current & Future Analysis for
Growth Factors by Type - Blood GrowthFactors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and Tissue GrowthFactors
Markets Independently Analyzed with AnnualSales in US$ Million for Years
2007 through 2015(includes corresponding Graph/Chart) 110
- Table 41: Rest of World Historic Review for GrowthFactors by Type -
Blood Growth Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors Markets
IndependentlyAnalyzed with Annual Sales in US$ Million forYears 2000 through
2006 (includes corresponding Graph/Chart) 111
- Table 42: Rest of World 11-Year Perspective for Growth Factors by Type
- Percentage Breakdown of Value Salesfor Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins)
andTissue Growth Factors Markets for 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 112
COMPETITIVE LANDSCAPE
|
 |
